{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,9]],"date-time":"2026-05-09T11:13:12Z","timestamp":1778325192295,"version":"3.51.4"},"reference-count":54,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,11,26]],"date-time":"2025-11-26T00:00:00Z","timestamp":1764115200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,11,26]],"date-time":"2025-11-26T00:00:00Z","timestamp":1764115200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["AAPS PharmSciTech"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Breast cancer is a prevalent malignancy that can metastasize to distant organs if left untreated, leading to significant morbidity. While chemotherapy is commonly used, it has drawbacks like low tissue availability, short circulation time, and toxicity to healthy cells. The objective of this study was to develop and characterize three different nanovesicles loaded with doxorubicin hydrochloride and paclitaxel, hypothesizing that this combination would enhance tumor targeting, reduce dosing and toxicity, and improve patient compliance. A validated UPLC method was developed for simultaneous detection and quantitation of both drugs, showing linearity over 3.13\u201350\u00a0\u00b5g\/mL. Retention times were 1.53 and 4.06\u00a0min for doxorubicin hydrochloride and paclitaxel, respectively. Using thin-film hydration technique, blank and drug-loaded liposomes, transfersomes, and niosomes were formulated. Nanovesicles were characterized for size (150\u2013250\u00a0nm), polydispersity index (0.14\u20130.20), and zeta potential (-0.56 to\u2009+\u20090.54\u00a0mV). Drug loading was 2.0\u20132.5% for doxorubicin hydrochloride and 7.0\u20137.5% for paclitaxel, with high encapsulation efficiency. Drug release studies showed sustained release for up to 72\u00a0h. Nanovesicles remained stable for at least seven days at room temperature and 4\u2070C. Cytotoxicity and apoptosis studies using MTT assay and flow cytometry on MDA-MB 231 breast cancer cells revealed that the drug-loaded nanovesicles exhibited potent cytotoxicity and induced apoptotic cell death more effectively than individual drug solutions. In conclusion, this study successfully developed three nanovesicular systems co-loaded with doxorubicin hydrochloride and paclitaxel, demonstrating their potential as effective drug delivery systems for breast cancer treatment.<\/jats:p>\n                  <jats:p>\n                    <jats:bold>Graphical Abstract<\/jats:bold>\n                  <\/jats:p>\n                  <jats:p>\n                    Created in BioRender. Dang, L. (2025)\n                    <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" xlink:href=\"https:\/\/BioRender.com\/h14t77\" ext-link-type=\"uri\">https:\/\/BioRender.com\/h14t77<\/jats:ext-link>\n                  <\/jats:p>","DOI":"10.1208\/s12249-025-03299-x","type":"journal-article","created":{"date-parts":[[2025,11,26]],"date-time":"2025-11-26T21:01:02Z","timestamp":1764190862000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Co-Encapsulation of Doxorubicin HCl and Paclitaxel in Nanovesicles for Enhanced Breast Cancer Therapy"],"prefix":"10.1208","volume":"27","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5312-913X","authenticated-orcid":false,"given":"Urmila","family":"Kafle","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-1418-8223","authenticated-orcid":false,"given":"Erik","family":"Moore","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-8313-308X","authenticated-orcid":false,"given":"Alexander","family":"Lushnikov","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6630-5865","authenticated-orcid":false,"given":"Alekha K.","family":"Dash","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,11,26]]},"reference":[{"key":"3299_CR1","unstructured":"Breast cancer. Available from: https:\/\/www.who.int\/news-room\/fact-sheets\/detail\/breast-cancer. Accessed 2024-08-13."},{"issue":"5","key":"3299_CR2","doi-asserted-by":"publisher","first-page":"822","DOI":"10.1158\/1055-9965.EPI-20-1193","volume":"30","author":"SC Houghton","year":"2021","unstructured":"Houghton SC, Hankinson SE. Cancer progress and priorities: breast cancer. Cancer Epidemiol Biomarkers Prev. 2021;30(5):822\u201344.","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"key":"3299_CR3","unstructured":"Breast Cancer Facts & Stats 2024 - Incidence, Age, Survival, & More. National Breast Cancer Foundation [cited 2024\u201308\u201313 23:12:51; Available from: https:\/\/www.nationalbreastcancer.org\/breast-cancer-facts\/. Accessed 2024-08-13."},{"issue":"8","key":"3299_CR4","doi-asserted-by":"publisher","first-page":"591","DOI":"10.1038\/nrc1670","volume":"5","author":"B Weigelt","year":"2005","unstructured":"Weigelt B, Peterse JL, van \u2019t Veer LJ. Breast cancer metastasis: markers and models. Nat Rev Cancer. 2005;5(8):591\u2013602.","journal-title":"Nat Rev Cancer"},{"issue":"5","key":"3299_CR5","first-page":"311","volume":"9","author":"OJ Scully","year":"2012","unstructured":"Scully OJ, et al. Breast cancer metastasis. Cancer Genomics Proteomics. 2012;9(5):311\u201320.","journal-title":"Cancer Genomics Proteomics"},{"issue":"2","key":"3299_CR6","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1016\/j.gendis.2018.05.001","volume":"5","author":"Y Feng","year":"2018","unstructured":"Feng Y, et al. Breast cancer development and progression: risk factors, cancer stem cells, signaling pathways, genomics, and molecular pathogenesis. Genes Dis. 2018;5(2):77\u2013106.","journal-title":"Genes Dis"},{"issue":"7","key":"3299_CR7","doi-asserted-by":"publisher","first-page":"1291","DOI":"10.1093\/annonc\/mdv022","volume":"26","author":"S Shiovitz","year":"2015","unstructured":"Shiovitz S, Korde LA. Genetics of breast cancer: a topic in evolution. Ann Oncol. 2015;26(7):1291\u20139.","journal-title":"Ann Oncol"},{"issue":"1","key":"3299_CR8","doi-asserted-by":"publisher","first-page":"20301","DOI":"10.1038\/s41598-023-45693-0","volume":"13","author":"LM Gearhart-Serna","year":"2023","unstructured":"Gearhart-Serna LM, et al. Cumulative environmental quality is associated with breast cancer incidence differentially by summary stage and urbanicity. Sci Rep. 2023;13(1):20301.","journal-title":"Sci Rep"},{"issue":"2","key":"3299_CR9","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1016\/j.soncn.2017.02.009","volume":"33","author":"C Coleman","year":"2017","unstructured":"Coleman C. Early detection and screening for breast cancer. Semin Oncol Nurs. 2017;33(2):141\u201355.","journal-title":"Semin Oncol Nurs"},{"key":"3299_CR10","doi-asserted-by":"publisher","first-page":"39","DOI":"10.21037\/sci.2018.10.05","volume":"5","author":"F Saeg","year":"2018","unstructured":"Saeg F, Anbalagan M. Breast cancer stem cells and the challenges of eradication: a review of novel therapies. Stem Cell Investig. 2018;5:39.","journal-title":"Stem Cell Investig"},{"issue":"12","key":"3299_CR11","doi-asserted-by":"publisher","DOI":"10.3390\/pharmaceutics14122783","volume":"14","author":"U Kafle","year":"2022","unstructured":"Kafle U, Agrawal S, Dash AK. Injectable nano drug delivery systems for the treatment of breast cancer. Pharmaceutics. 2022;14(12): 2783.","journal-title":"Pharmaceutics"},{"issue":"5","key":"3299_CR12","doi-asserted-by":"publisher","first-page":"212","DOI":"10.1186\/bcr2647","volume":"12","author":"CA Gabriel","year":"2010","unstructured":"Gabriel CA, Domchek SM. Breast cancer in young women. Breast Cancer Res. 2010;12(5):212.","journal-title":"Breast Cancer Res"},{"issue":"1","key":"3299_CR13","doi-asserted-by":"publisher","DOI":"10.1038\/s41523-023-00508-3","volume":"9","author":"V Debien","year":"2023","unstructured":"Debien V, et al. Immunotherapy in breast cancer: an overview of current strategies and perspectives. NPJ Breast Cancer. 2023;9(1): 7.","journal-title":"NPJ Breast Cancer"},{"issue":"14","key":"3299_CR14","doi-asserted-by":"publisher","DOI":"10.3390\/ijms25147517","volume":"25","author":"K Dvir","year":"2024","unstructured":"Dvir K, Giordano S, Leone JP. Immunotherapy in breast cancer. Int J Mol Sci. 2024;25(14): 7517.","journal-title":"Int J Mol Sci"},{"issue":"3","key":"3299_CR15","doi-asserted-by":"publisher","first-page":"218","DOI":"10.3121\/cmr.4.3.218","volume":"4","author":"D Cross","year":"2006","unstructured":"Cross D, Burmester JK. Gene therapy for cancer treatment: past, present and future. Clin Med Res. 2006;4(3):218\u201327.","journal-title":"Clin Med Res"},{"issue":"12","key":"3299_CR16","doi-asserted-by":"publisher","first-page":"723","DOI":"10.1016\/j.mpmed.2011.09.006","volume":"39","author":"J Abraham","year":"2011","unstructured":"Abraham J, Staffurth J. Hormonal therapy for cancer. Medicine (Baltimore). 2011;39(12):723\u20137.","journal-title":"Medicine (Baltimore)"},{"key":"3299_CR17","doi-asserted-by":"publisher","first-page":"458","DOI":"10.1016\/j.biopha.2018.02.108","volume":"101","author":"M Abotaleb","year":"2018","unstructured":"Abotaleb M, et al. Chemotherapeutic agents for the treatment of metastatic breast cancer: an update. Biomed Pharmacother. 2018;101:458\u201377.","journal-title":"Biomed Pharmacother"},{"issue":"7","key":"3299_CR18","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1093\/oxfordjournals.annonc.a010717","volume":"7","author":"J Gehl","year":"1996","unstructured":"Gehl J, et al. Combined doxorubicin and paclitaxel in advanced breast cancer: effective and cardiotoxic. Ann Oncol. 1996;7(7):687\u201393.","journal-title":"Ann Oncol"},{"key":"3299_CR19","unstructured":"National Center for Biotechnology Information (2024). PubChem Compound Summary for CID 31703, D.R.A., 2024 from https:\/\/pubchem.ncbi.nlm.nih.gov\/compound\/Doxorubicin. Accessed 20 August 2024."},{"key":"3299_CR20","unstructured":"National Center for Biotechnology Information (2024). PubChem Compound Summary for CID 36314, P.R.A., 2024 from https:\/\/pubchem.ncbi.nlm.nih.gov\/compound\/Paclitaxel. Accessed 20 August 2024."},{"issue":"2","key":"3299_CR21","doi-asserted-by":"publisher","first-page":"434","DOI":"10.1177\/1078155219877931","volume":"26","author":"HS Al-Malky","year":"2020","unstructured":"Al-Malky HS, Al Harthi SE, Osman A-MM. Major obstacles to doxorubicin therapy: cardiotoxicity and drug resistance. J Oncol Pharm Pract. 2020;26(2):434\u201344.","journal-title":"J Oncol Pharm Pract"},{"issue":"1","key":"3299_CR22","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1016\/j.ejca.2005.06.030","volume":"42","author":"S Mielke","year":"2006","unstructured":"Mielke S, Sparreboom A, Mross K. Peripheral neuropathy: a persisting challenge in paclitaxel-based regimes. Eur J Cancer. 2006;42(1):24\u201330.","journal-title":"Eur J Cancer"},{"key":"3299_CR23","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1016\/j.addr.2012.09.006","volume":"64","author":"I Brigger","year":"2012","unstructured":"Brigger I, Dubernet C, Couvreur P. Nanoparticles in cancer therapy and diagnosis. Adv Drug Deliv Rev. 2012;64:24\u201336.","journal-title":"Adv Drug Deliv Rev"},{"issue":"11","key":"3299_CR24","doi-asserted-by":"publisher","first-page":"1649","DOI":"10.1016\/j.addr.2004.02.014","volume":"56","author":"L Brannon-Peppas","year":"2004","unstructured":"Brannon-Peppas L, Blanchette JO. Nanoparticle and targeted systems for cancer therapy. Adv Drug Deliv Rev. 2004;56(11):1649\u201359.","journal-title":"Adv Drug Deliv Rev"},{"key":"3299_CR25","doi-asserted-by":"publisher","unstructured":"Marzagalli M, et al. Cancer stem cells-key players in tumor relapse. Cancers (Basel). 2021;13(3). https:\/\/doi.org\/10.3390\/cancers13030376.","DOI":"10.3390\/cancers13030376"},{"key":"3299_CR26","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1016\/j.biomaterials.2016.04.027","volume":"97","author":"C N\u00fa\u00f1ez","year":"2016","unstructured":"N\u00fa\u00f1ez C, et al. An overview of the effective combination therapies for the treatment of breast cancer. Biomaterials. 2016;97:34\u201350.","journal-title":"Biomaterials"},{"issue":"8","key":"3299_CR27","doi-asserted-by":"publisher","first-page":"808","DOI":"10.3390\/jpm11080808","volume":"11","author":"A Burguin","year":"2021","unstructured":"Burguin A, Diorio C, Durocher F. Breast cancer treatments: updates and new challenges. J Pers Med. 2021;11(8):808.","journal-title":"J Pers Med"},{"issue":"5","key":"3299_CR28","doi-asserted-by":"publisher","first-page":"357","DOI":"10.4155\/tde-2023-0020","volume":"14","author":"JA Malik","year":"2023","unstructured":"Malik JA, et al. Nano-drug delivery system: a promising approach against breast cancer. Ther Deliv. 2023;14(5):357\u201381.","journal-title":"Ther Deliv"},{"issue":"1","key":"3299_CR29","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1016\/j.addr.2012.09.037","volume":"65","author":"TM Allen","year":"2013","unstructured":"Allen TM, Cullis PR. Liposomal drug delivery systems: from concept to clinical applications. Adv Drug Deliv Rev. 2013;65(1):36\u201348.","journal-title":"Adv Drug Deliv Rev"},{"issue":"1","key":"3299_CR30","doi-asserted-by":"publisher","first-page":"1325708","DOI":"10.1080\/20022727.2017.1325708","volume":"8","author":"S Rai","year":"2017","unstructured":"Rai S, Pandey V, Rai G. Transfersomes as versatile and flexible nano-vesicular carriers in skin cancer therapy: the state of the art. Nano Reviews and Experiment. 2017;8(1):1325708.","journal-title":"Nano Reviews and Experiment"},{"issue":"1","key":"3299_CR31","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1016\/S0005-2736(02)00401-7","volume":"1564","author":"G Cevc","year":"2002","unstructured":"Cevc G, Sch\u00e4tzlein A, Richardsen H. Ultradeformable lipid vesicles can penetrate the skin and other semi-permeable barriers unfragmented. Evidence from double label CLSM experiments and direct size measurements. Biochim Biophys Acta. 2002;1564(1):21\u201330.","journal-title":"Biochim Biophys Acta"},{"issue":"5","key":"3299_CR32","doi-asserted-by":"publisher","first-page":"3597","DOI":"10.1007\/s11033-022-07199-2","volume":"49","author":"B Pourmoghadasiyan","year":"2022","unstructured":"Pourmoghadasiyan B, et al. Nanosized paclitaxel-loaded niosomes: formulation, in vitro cytotoxicity, and apoptosis gene expression in breast cancer cell lines. Mol Biol Rep. 2022;49(5):3597\u2013608.","journal-title":"Mol Biol Rep"},{"issue":"4","key":"3299_CR33","doi-asserted-by":"publisher","first-page":"42","DOI":"10.3390\/colloids8040042","volume":"8","author":"II Mota D\u00edaz","year":"2024","unstructured":"Mota D\u00edaz II, et al. Co-encapsulation of Paclitaxel and Doxorubicin in liposomes layer by layer. Colloids Interfaces. 2024;8(4):42.","journal-title":"Colloids Interfaces"},{"issue":"10","key":"3299_CR34","doi-asserted-by":"publisher","first-page":"1479","DOI":"10.1248\/bpb.b23-00188","volume":"46","author":"M Hosokawa","year":"2023","unstructured":"Hosokawa M, et al. Preparation and evaluation of paclitaxel-loaded PEGylated niosomes composed of sorbitan esters. Biol Pharm Bull. 2023;46(10):1479\u201383.","journal-title":"Biol Pharm Bull"},{"key":"3299_CR35","doi-asserted-by":"publisher","first-page":"512","DOI":"10.1016\/j.jconrel.2022.03.043","volume":"345","author":"M Ikeda-Imafuku","year":"2022","unstructured":"Ikeda-Imafuku M, et al. Strategies to improve the EPR effect: a mechanistic perspective and clinical translation. J Control Release. 2022;345:512\u201336.","journal-title":"J Control Release"},{"key":"3299_CR36","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1016\/j.ejpb.2023.04.016","volume":"188","author":"N Rezaei","year":"2023","unstructured":"Rezaei N, et al. Co-delivery of doxorubicin and paclitaxel via noisome nanocarriers attenuates cancerous phenotypes in gastric cancer cells. Eur J Pharm Biopharm. 2023;188:33\u201347.","journal-title":"Eur J Pharm Biopharm"},{"key":"3299_CR37","unstructured":"Guideline IHT. Validation of analytical procedures: text and methodology. Q2 (R1), 2005;1(20):05."},{"key":"3299_CR38","doi-asserted-by":"crossref","unstructured":"Swartz ME, Krull IS. Handbook of analytical validation. 1st ed. CRC Press. 2012.","DOI":"10.1201\/b12039"},{"key":"3299_CR39","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1016\/j.ymeth.2021.05.004","volume":"199","author":"Y Thabet","year":"2022","unstructured":"Thabet Y, Elsabahy M, Eissa NG. Methods for preparation of niosomes: a focus on thin-film hydration method. Methods. 2022;199:9\u201315.","journal-title":"Methods"},{"issue":"8","key":"3299_CR40","doi-asserted-by":"publisher","first-page":"787","DOI":"10.1080\/10837450.2017.1330345","volume":"23","author":"A Ahad","year":"2018","unstructured":"Ahad A, et al. Formulation and characterization of Phospholipon 90 G and tween 80 based transfersomes for transdermal delivery of eprosartan mesylate. Pharm Dev Technol. 2018;23(8):787\u201393.","journal-title":"Pharm Dev Technol"},{"issue":"8","key":"3299_CR41","doi-asserted-by":"publisher","first-page":"1789","DOI":"10.3390\/foods10081789","volume":"10","author":"H Kanda","year":"2021","unstructured":"Kanda H, et al. Preparation of Liposomes from Soy Lecithin Using Liquefied Dimethyl Ether. Foods. 2021;10(8):1789.","journal-title":"Foods"},{"issue":"17","key":"3299_CR42","doi-asserted-by":"publisher","DOI":"10.3390\/ijms241713542","volume":"24","author":"S Pisani","year":"2023","unstructured":"Pisani S, et al. Investigation and comparison of active and passive encapsulation methods for loading proteins into liposomes. Int J Mol Sci. 2023;24(17): 13542.","journal-title":"Int J Mol Sci"},{"issue":"1","key":"3299_CR43","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1016\/j.jconrel.2009.05.036","volume":"139","author":"D Zucker","year":"2009","unstructured":"Zucker D, et al. Liposome drugs\u2019 loading efficiency: a working model based on loading conditions and drug\u2019s physicochemical properties. J Control Release. 2009;139(1):73\u201380.","journal-title":"J Control Release"},{"key":"3299_CR44","unstructured":"Kafle U. Nanovesicles delivery systems containing doxorubicin hydrochloride and paclitaxel for the treatment of breast cancer. Creighton University: United States Nebraska 2023:125.\u00a0http:\/\/search.proquest.com.ezproxy.lib.uh.edu\/dissertations-theses\/nanovesicles-delivery-systems-containing\/docview\/2822869312\/se-2."},{"issue":"7","key":"3299_CR45","doi-asserted-by":"publisher","DOI":"10.3390\/pharmaceutics13071052","volume":"13","author":"YR Neupane","year":"2021","unstructured":"Neupane YR, et al. Lyophilization preserves the intrinsic cardioprotective activity of bioinspired cell-derived nanovesicles. Pharmaceutics. 2021;13(7): 1052.","journal-title":"Pharmaceutics"},{"issue":"9","key":"3299_CR46","doi-asserted-by":"publisher","first-page":"2143","DOI":"10.1002\/cplu.202000496","volume":"85","author":"Y Liu","year":"2020","unstructured":"Liu Y, et al. Development of high-drug-loading nanoparticles. ChemPlusChem. 2020;85(9):2143\u201357.","journal-title":"ChemPlusChem"},{"issue":"1\u20132","key":"3299_CR47","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1016\/0022-1759(86)90215-2","volume":"94","author":"D Gerlier","year":"1986","unstructured":"Gerlier D, Thomasset N. Use of MTT colorimetric assay to measure cell activation. J Immunol Methods. 1986;94(1\u20132):57\u201363.","journal-title":"J Immunol Methods"},{"key":"3299_CR48","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1007\/978-1-61779-080-5_20","volume-title":"Cancer Cell Culture: Methods and Protocols","author":"J van Meerloo","year":"2011","unstructured":"van Meerloo J, Kaspers GJL, Cloos J. Cell Sensitivity Assays: The MTT Assay. In: Cree IA, editor. Cancer Cell Culture: Methods and Protocols. Totowa, NJ: Humana Press; 2011. p. 237\u201345."},{"issue":"15","key":"3299_CR49","doi-asserted-by":"publisher","first-page":"1688","DOI":"10.1016\/j.addr.2006.09.017","volume":"58","author":"W Abdelwahed","year":"2006","unstructured":"Abdelwahed W, et al. Freeze-drying of nanoparticles: formulation, process and storage considerations. Adv Drug Deliv Rev. 2006;58(15):1688\u2013713.","journal-title":"Adv Drug Deliv Rev"},{"issue":"2","key":"3299_CR50","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1016\/S0378-5173(97)00222-6","volume":"157","author":"C Schwarz","year":"1997","unstructured":"Schwarz C, Mehnert W. Freeze-drying of drug-free and drug-loaded solid lipid nanoparticles (SLN). Int J Pharm. 1997;157(2):171\u20139.","journal-title":"Int J Pharm"},{"issue":"1","key":"3299_CR51","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1016\/S0005-2736(00)00251-0","volume":"1468","author":"SD Allison","year":"2000","unstructured":"Allison SD, Molina MdC, Anchordoquy TJ. Stabilization of lipid\/DNA complexes during the freezing step of the lyophilization process: the particle isolation hypothesis. Biochimica et Biophysica Acta (BBA) - Biomembranes. 2000;1468(1):127\u201338.","journal-title":"Biochimica et Biophysica Acta (BBA) - Biomembranes"},{"issue":"11","key":"3299_CR52","doi-asserted-by":"publisher","first-page":"2169","DOI":"10.1002\/1097-0142(20001201)89:11<2169::AID-CNCR4>3.0.CO;2-9","volume":"89","author":"A Lluch","year":"2000","unstructured":"Lluch A, et al. Doxorubicin and paclitaxel in advanced breast carcinoma. Cancer. 2000;89(11):2169\u201375.","journal-title":"Cancer"},{"key":"3299_CR53","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijpharm.2020.119183","volume":"580","author":"Y Zhang","year":"2020","unstructured":"Zhang Y, et al. Sodium dodecyl sulfate improved stability and transdermal delivery of salidroside-encapsulated niosomes via effects on zeta potential. Int J Pharm. 2020;580: 119183.","journal-title":"Int J Pharm"},{"issue":"4","key":"3299_CR54","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1208\/s12249-023-02550-7","volume":"24","author":"D Kumar","year":"2023","unstructured":"Kumar D, et al. Structural changes in liposomal vesicles in association with sodium taurodeoxycholate. AAPS PharmSciTech. 2023;24(4):95.","journal-title":"AAPS PharmSciTech"}],"container-title":["AAPS PharmSciTech"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1208\/s12249-025-03299-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1208\/s12249-025-03299-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1208\/s12249-025-03299-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,5]],"date-time":"2026-02-05T19:02:42Z","timestamp":1770318162000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1208\/s12249-025-03299-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,26]]},"references-count":54,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,1]]}},"alternative-id":["3299"],"URL":"https:\/\/doi.org\/10.1208\/s12249-025-03299-x","relation":{},"ISSN":["1530-9932"],"issn-type":[{"value":"1530-9932","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,26]]},"assertion":[{"value":"31 July 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 November 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 November 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This research was conducted by the ethical standards and guidelines set forth by Creighton University.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics Statement"}},{"value":"We confirm that there are no conflicts of interest associated with this work and that there has been no significant financial support for this work that could have influenced its outcome.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"The views and opinions expressed in this research paper are those of the author(s) and do not necessarily reflect the official policy or position of Creighton University. The information contained in this paper is for general informational purposes only. While the author(s) have made every effort to ensure the accuracy and completeness of the information presented, Creighton University makes no representations or warranties of any kind, express or implied, about the completeness, accuracy, reliability, suitability, or availability concerning the paper or the information, products, services, or related graphics contained in the paper for any purpose. Any reliance you place on such information is therefore strictly at your own risk. In no event will Creighton University be liable for any loss or damage, including without limitation, indirect or consequential loss or damage, or any loss or damage whatsoever arising from loss of data or profits arising out of, or in connection with, the use of this paper.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Disclaimer"}}],"article-number":"41"}}